NCT06963814View on ClinicalTrials.gov

Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

252

Participants

Timeline

Start Date

July 4, 2025

Primary Completion Date

May 30, 2026

Study Completion Date

May 30, 2027

Conditions

Advanced Cancer

Interventions

DRUG

HC006

Specified dose on specified days

DRUG

KEYTRUDA ®( Pembrolizumab)

Specified dose on specified days

Trial Locations (1)

200123

RECRUITING

Shanghai East Hospital, Shanghai

Sponsors

Lead Sponsor

HC Biopharma Inc.

All Listed Sponsors

lead

HC Biopharma Inc.

INDUSTRY

NCT06963814 - Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter